# Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

> **NCT04220775** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Head and Neck Squamous Cell Carcinoma
- Second Primary Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Bintrafusp Alfa
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT04220775
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-18
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-10-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The sponsor decided to no longer develop the drug and stop support of studies using the drug.
- **Last updated:** 2024-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220775, "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04220775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*